Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)

C. Mathieu*, A. H. Barnett, H. Brath, I. Conget, J. J. de Castro, R. Goeke, E. Marquez Rodriguez, P. M. Nilsson, E. Pagkalos, A. Penfornis, N. C. Schaper, S. K. Wangnoo, W. Kothny, G. Bader

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aim Real-life studies are needed to confirm the clinical relevance of findings from randomised controlled trials (RCTs). This study aimed to assess the effectiveness and tolerability of vildagliptin add-on vs. other oral antihyperglycaemic drugs (OADs) added to OAD monotherapy in a real-life setting, and to explore the advantages and limitations of large-scale pragmatic' trials. MethodsEDGE was a prospective, 1-year, worldwide, real-life observational study in which 2957 physicians reported on the effects of second-line OADs in 45,868 patients with T2DM not reaching glycaemic targets with monotherapy. Physicians could add any OAD, and patients entered either vildagliptin or (pooled) comparator cohort. The primary effectiveness and tolerability end-point (PEP) evaluated proportions of patients decreasing HbA(1c)>0.3%, without hypoglycaemia, weight gain, peripheral oedema or gastrointestinal side effects. The most clinically relevant secondary end-point (SEP 3) was attainment of end-point HbA(1c)
Original languageEnglish
Pages (from-to)947-956
JournalInternational Journal of Clinical Practice
Issue number10
Publication statusPublished - Oct 2013

Cite this